Financial Data and Key Metrics Changes - Novanta reported record revenue in Q4 2025 with a 9% reported growth, 2% organic growth, and 4% sequential growth [5] - Full-year revenue reached $981 million, marking the largest year in the company's history, with full-year bookings growing by 14% [5] - Adjusted EBITDA grew by 17% year-over-year, and Adjusted Diluted EPS increased by 20% [6][23] - Non-GAAP adjusted gross profit for Q4 was $118 million, with a 45.5% adjusted gross margin, down from 47% in Q4 2024 [21] - Operating cash flow in Q4 was $9 million, significantly lower than $62 million in Q4 2024, impacted by regional manufacturing dynamics [24] Business Line Data and Key Metrics Changes - New product revenue grew over 60% for the full year, with over 80% growth in Q4 [6][20] - Automation Enabling Technologies segment revenue grew by 2% year-over-year, with bookings up 33% [27] - Precision Manufacturing Business saw a 3% revenue decline year-over-year in Q4 but had an 8% sequential growth [27] - Medical Solutions segment revenue grew by 16% year-over-year in Q4, with advanced surgery business growing 15% [30] Market Data and Key Metrics Changes - Sales in medical end markets represented 53% of total sales, while advanced industrial markets accounted for 47% [20] - Medical consumable sales grew at a strong double-digit rate, representing 15% of total company sales [20] - The Robotics & Automation business is expected to see high single-digit growth in 2026, driven by AI-driven tailwinds [12][13] Company Strategy and Development Direction - Novanta's long-term growth strategy focuses on high-growth end markets such as AI-driven Robotics & Automation, minimally invasive surgery, and precision medicine [8] - The company aims to expand its business mix and technology leadership in medical technologies and embedded software [9] - Acquisitions are a key growth strategy, with a pipeline focused on mid to larger opportunities in medical technologies and consumables [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving mid-single-digit organic growth in 2026, supported by strong bookings and new product launches [10][18] - The company anticipates a significant inventory drawdown and strong cash rebound as regional manufacturing initiatives are completed [24] - Management highlighted the importance of customer relationships and the need for capable suppliers in the medical technology space [84] Other Important Information - The company ended Q4 with gross debt of $260 million and a net cash position for the first time in over a decade [25] - Novanta's acquisition capacity stands at nearly $1.5 billion, with a robust acquisition pipeline [42] Q&A Session Summary Question: Can you elaborate on the increase in bookings in the Automation Enabling Technologies segment? - Management noted broad-based growth across all businesses, with strong momentum in Robotics & Automation driven by precision robotics and semiconductor capital equipment [46][47] Question: What is the revenue expectation for the industrial robotics order announced previously? - Management indicated that revenue from the order will ramp modestly this year, with expectations for sequential growth [54] Question: How does the company reconcile strong bookings momentum with EPS growth expectations? - Management explained that the EPS growth is impacted by the recent fundraise and an all-employee equity grant, but organic growth remains strong [62][63] Question: Can you provide insights on the GPU boards opportunity? - Management highlighted that the company is the leader in drilling for GPU boards, with increasing demand from new end users in the AI space [67][68] Question: Is the positive book-to-bill across all business units? - Management confirmed that all four business units had a positive book-to-bill ratio, indicating strong momentum and backlog growth [71][72]

Financial Data and Key Metrics Changes - Novanta reported record revenue in Q4 2025 with a 9% reported growth, 2% organic growth, and 4% sequential growth [5] - Full-year revenue reached $981 million, marking the largest year in the company's history, with full-year bookings growing by 14% [5] - Adjusted EBITDA grew by 17% year-over-year, and adjusted diluted EPS increased by 20% [6][23] - Non-GAAP adjusted gross profit for Q4 was $118 million, with a 45.5% adjusted gross margin, down from 47% in Q4 2024 [21] Business Line Data and Key Metrics Changes - New product revenue grew over 60% for the full year, with over 80% growth in Q4 [6][20] - The Automation Enabling Technologies segment saw a 2% year-over-year revenue growth in Q4, with bookings up 33% [27] - The Medical Solutions segment experienced a 16% year-over-year revenue growth in Q4, with bookings up 17% [29] Market Data and Key Metrics Changes - Sales in medical end markets represented 53% of total sales, while advanced industrial markets accounted for 47% [20] - The advanced surgery business grew by 15% year-over-year, driven by strong procedural growth and new product launches [29] - The precision manufacturing business saw a year-over-year revenue decline of 3% in Q4 but had double-digit bookings growth [27] Company Strategy and Development Direction - Novanta's long-term growth strategy focuses on high-growth end markets such as AI-driven robotics, minimally invasive surgery, and precision medicine [8] - The company aims to achieve mid-single-digit organic growth in 2026, supported by strong bookings and new product launches [10] - Acquisitions are a key growth strategy, with a pipeline focused on mid to larger opportunities in medical technologies and embedded software [10][41] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in returning to mid-single-digit organic growth, driven by strong demand and a recovering semiconductor market [10][12] - The company anticipates a significant inventory drawdown and strong cash rebound as regional manufacturing initiatives are completed [24] - Management highlighted the importance of customer relationships and the need for capable suppliers in the medical technology space [82] Other Important Information - The company ended Q4 with gross debt of $260 million and a net cash position for the first time in over a decade [25] - Operating cash flow for the full year was $64 million, impacted by regional manufacturing dynamics and higher inventory builds [24] - Novanta expects to achieve approximately 47% adjusted gross margin for the full year 2026, representing a 100 basis points expansion year-over-year [32] Q&A Session Summary Question: Can you discuss the sequential increase in bookings in the Automation Enabling Technologies segment? - Management noted broad-based growth across all businesses, with strong momentum in robotics and automation, particularly in precision robotics and semiconductor capital equipment [45][46] Question: What is the revenue expectation for the industrial robotics order announced previously? - Management indicated that revenue from the industrial robotics order will ramp modestly this year, with expectations for sequential growth [53] Question: How does the company reconcile strong bookings momentum with EPS growth expectations? - Management explained that the EPS growth is impacted by a recent fundraise and an all-employee equity grant, but organic growth remains strong [61][62] Question: Can you elaborate on the GPU boards opportunity? - Management highlighted that Novanta is the leader in drilling for GPU boards, with increasing demand from new end users in the AI space [66][68] Question: Is the positive book-to-bill metric applicable across all business units? - Management confirmed that all four business units had a positive book-to-bill ratio, indicating strong demand and backlog growth [70][72]

Financial Data and Key Metrics Changes - Novanta reported record revenue in Q4 2025 with 9% reported growth, 2% organic growth, and 4% sequential growth, achieving $981 million in revenue for the full year, the largest in its history [5][6] - Adjusted EBITDA grew by 17% year-over-year, and Adjusted Diluted EPS increased by 20% in Q4 2025 [6][24] - Non-GAAP adjusted gross profit for Q4 was $118 million, with a gross margin of 45.5%, down from 47% in Q4 2024 [21][24] - Operating cash flow in Q4 was $9 million, significantly lower than $62 million in Q4 2024, impacted by regional manufacturing dynamics and higher inventory [25][26] Business Line Data and Key Metrics Changes - New product revenue grew over 60% for the full year, with over 80% growth in Q4, indicating strong commercial excellence and innovation investments [6][20] - The Automation Enabling Technologies segment saw a 2% year-over-year revenue growth in Q4, with bookings up 33% [28] - The Medical Solutions segment experienced a 16% year-over-year revenue growth in Q4, with advanced surgery business growing 15% [30][31] Market Data and Key Metrics Changes - Sales in medical end markets represented 53% of total sales, while advanced industrial markets accounted for 47% [20] - The precision manufacturing business saw a year-over-year revenue decline of 3% in Q4 but had double-digit growth in bookings [28][30] - The robotics and automation business grew revenues by 6% year-over-year in Q4, benefiting from demand in advanced robotic applications [28] Company Strategy and Development Direction - Novanta's long-term growth strategy focuses on high-growth end markets such as AI-driven robotics, minimally invasive surgery, and precision medicine, with a target of $4 billion incremental market opportunity by 2030 [7][9] - The company aims to drive mid-single-digit organic growth in 2026, supported by record bookings and new product launches [10][18] - Acquisitions are a key growth strategy, with a pipeline focused on mid to larger opportunities in medical technologies and embedded software [10][43] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in returning to mid-single-digit organic growth, citing strong demand and a recovering semiconductor market [10][12] - The company anticipates a significant inventory drawdown and strong cash rebound as regional manufacturing initiatives are completed [25][26] - Management highlighted the importance of customer relationships and the ability to solve complex problems as a competitive advantage [82] Other Important Information - The company ended Q4 with gross debt of $260 million and a net cash position for the first time in over a decade [26] - Novanta's investments in intelligent RFID solutions and advanced machine vision technologies are expected to stabilize the outlook for the business [16] Q&A Session Summary Question: Can you elaborate on the sequential increase in bookings in the Automation Enabling Technologies segment? - Management noted broad-based growth across all businesses, with strong momentum in robotics and automation, particularly in precision robotics and semiconductor capital equipment [47][48] Question: What is the revenue expectation for the industrial robotics order announced previously? - Management indicated that revenue from the first phase of ramp will be modest this year, with sequential growth expected thereafter, highlighting technology leadership as a key factor [54][56] Question: How does the company reconcile strong bookings momentum with EPS growth expectations? - Management explained that the EPS growth is impacted by the recent fundraise and an all-employee equity grant, but organic growth remains strong despite these headwinds [62][63] Question: Can you provide insights on the GPU boards opportunity? - Management confirmed that they are the leading supplier for drilling AI-driven GPU boards, with strong demand expected to continue, indicating a multi-year growth trajectory [66][67] Question: Was the positive book-to-bill across all business units? - Management confirmed that all four business units had a positive book-to-bill ratio, indicating strong momentum and building backlog [71][72]